fda approved glp-1 agonists Patient education tips for GLP-1, weight loss drug treatment Comparing Ozempic, Wegovy and Other

Notably, these drugs are currently not covered for weight loss in Medicare, due to a long-time exclusion of treatment for weight loss

Average total body weight loss (TBWL) after one year on a GLP-1 semaglutide such as Wegovy and Ozempic is 12%15%, and on a GLP-1 tirzepatide like Mounjaro, & Zepbound is 21%

Summary: GLP-1-related fatigue typically improves within several weeks to a few months as the body adapts to treatment, though individual experiences vary considerably

Am J Physiol Cell Physiol 2024;326:C56772

Monitoring degradation behavior helps scientists predict shelf life and protect drug effectiveness

Data from the European LEOSS registry as well as other data show an additive effect of obesity, diabetes, and hypertension on the risk of mortality, which is higher in young and middle-aged patients (1855 years)